EFEMP1 Antibody

What is EFEMP1 and what are its key functional properties?

EFEMP1, a 54.6 kilodalton protein also known as Fibulin-3, FBLN3, FBNL, and FIBL-3, is an extracellular matrix glycoprotein that plays significant roles in cellular signaling and structural support. It exhibits functional relationships with proteins like fibronectin and integrins, highlighting its importance in mediating cell-matrix interactions and influencing signal transduction cascades . Structurally, EFEMP1 contains EGF-like domains that enable specific binding interactions.

The protein binds to EGFR (epidermal growth factor receptor), inducing EGFR autophosphorylation and activating downstream signaling pathways . EFEMP1 is involved in cell adhesion and migration processes and may function as a negative regulator of chondrocyte differentiation . In the olfactory epithelium, it appears to regulate glial cell migration, differentiation, and the ability of glial cells to support neuronal neurite outgrowth .

These multifaceted functions make EFEMP1 a protein of interest in studies ranging from developmental biology to cancer research, necessitating reliable antibodies for its detection and characterization.

How do I select the appropriate EFEMP1 antibody for my experimental applications?

Selecting the optimal EFEMP1 antibody requires consideration of several experimental parameters:

Application compatibility: Different antibodies perform optimally in specific applications. From the search results, EFEMP1 antibodies are available for various techniques including Western blotting (WB), immunohistochemistry (IHC-P), immunocytochemistry (ICC), immunofluorescence (ICC/IF), ELISA, and immunoprecipitation (IP) . Select an antibody validated for your specific application.

Species reactivity: EFEMP1 antibodies vary in their ability to recognize the protein across species. Common reactivities include human, mouse, and rat, though some antibodies recognize a broader range of species . Verify that your selected antibody recognizes EFEMP1 in your experimental model organism.

Clonality considerations: Both monoclonal and polyclonal EFEMP1 antibodies are available. Polyclonal antibodies (like GTX111657 and ab106429) recognize multiple epitopes, potentially providing stronger signals but with potential for less specificity . For highly specific detection of particular epitopes, consider monoclonal alternatives.

Validated performance: Look for antibodies with published citations and validation data. For example, GTX111657 has been cited in at least three publications and includes supporting experimental figures .

Immunogen information: Understanding the immunogen used to generate the antibody helps predict binding specificity. For instance, ab106429 was generated using a synthetic peptide within Human EFEMP1 .

By systematically evaluating these factors, researchers can select EFEMP1 antibodies that will produce reliable results for their specific experimental needs.

What are the optimal protocols for Western blot detection of EFEMP1?

The following protocol is based on validated methodologies used with commercial EFEMP1 antibodies:

Sample preparation and loading:

• Prepare whole cell extracts (approximately 30 μg protein) or tissue extracts (approximately 50 μg protein)

• Separate proteins using 10% SDS-PAGE gel electrophoresis

Transfer and antibody incubation:

• Transfer separated proteins to a membrane using standard protocols

• Block the membrane with appropriate blocking buffer

• For primary antibody incubation:

  • GTX111657 antibody: Use at 1:1000 dilution for cell lines and tissue extracts, or 1:5000 for transfected/non-transfected samples

  • Follow with appropriate HRP-conjugated secondary antibody (e.g., anti-rabbit IgG)

Signal detection:

• Develop signal using a chemiluminescent substrate system, such as Trident femto Western HRP Substrate

• Exposure time may need optimization based on expression levels

Expected results:
EFEMP1 should be detected at approximately 54-55 kDa. Expression levels vary significantly between different cell types and tissues, with correlation to RNA expression data observed in validated studies .

If encountering weak signals, consider concentrating the protein sample, reducing primary antibody dilution, or extending incubation times. For high background, increase washing steps and optimize blocking conditions.

How can I utilize EFEMP1 antibodies in immunohistochemistry (IHC) applications?

The following immunohistochemistry protocol has been successfully employed for EFEMP1 detection in tissue samples:

Tissue preparation:

• Prepare 4-5 μm tissue sections from formalin-fixed paraffin-embedded tissue blocks

• Deparaffinize and rehydrate sections in xylene and graded alcohols

• Perform antigen retrieval using 0.01 M sodium citrate buffer (pH 6.0) heated in a microwave oven

Antibody incubation:

• Incubate tissue sections with anti-EFEMP1 antibody:

  • For example, Abgent AP9095a at 1:50 dilution in a humidified container at 4°C overnight

  • Alternative validated antibodies like GTX111657 have also shown efficacy in IHC-P applications

• For negative controls, substitute primary antibody with PBS

• Incubate with appropriate HRP-conjugated secondary antibody system (e.g., EnVision-HRP)

Signal development and analysis:

• Develop with DAB or other appropriate chromogen

• For quantification, select at least five randomly chosen regions from each tissue section

• Measure integral optical density and area using image analysis software such as Image-Pro Plus

• Calculate the average optical density to represent expression intensity for each section

This protocol allows for both qualitative assessment of EFEMP1 expression patterns and semi-quantitative analysis of expression levels in tissue samples.

What is the recommended ELISA procedure for quantifying EFEMP1 in serum samples?

For precise quantification of EFEMP1 protein in serum samples, the following ELISA protocol has been validated in clinical research:

Reagents and materials:

• Commercial sandwich ELISA kit for EFEMP1/Fibulin-3 detection (e.g., Cloud-Clone Corp. SEF422Hu)

• PBS for sample dilution

• Serum samples (fresh or appropriately stored)

Procedure:

• Dilute serum samples in PBS according to expected concentration range

• Add 100 μL of diluted samples to pre-coated wells

• Follow manufacturer's protocol for incubation times, washing steps, and detection reagents

• Measure optical density using a microplate reader at the wavelength specified by the kit manufacturer

• Calculate EFEMP1 concentration using a standard curve generated with known concentrations

Data interpretation:

• Normal healthy controls exhibit mean serum EFEMP1 levels of approximately 1.47 ng/ml (SD ±1.65)

• Elevated levels may be observed in certain pathological conditions; for instance, osteosarcoma patients show significantly higher mean levels of 7.61 ng/ml (SD ±8.76)

• Establish appropriate cutoff values for your specific research context based on ROC curve analysis

This ELISA methodology provides quantitative assessment of EFEMP1 levels with high sensitivity and has been successfully employed in clinical biomarker studies.

How can EFEMP1 be used as a biomarker in cancer research?

EFEMP1 shows significant potential as a biomarker in cancer research, particularly in osteosarcoma (OS). The following methodological approaches have been validated for using EFEMP1 in cancer biomarker studies:

Serum quantification approach:

• Measure serum EFEMP1 levels using standardized ELISA protocols as described in section 2.3

• Establish diagnostic cutoff values through ROC curve analysis

• For OS diagnosis, a cutoff value of 1.51 ng/ml has demonstrated an area under the curve (AUC) of 0.83 (95% CI = 0.76-0.91), with 88.24% sensitivity and 68.12% specificity

Correlation with clinical parameters:

• Examine associations between EFEMP1 levels and clinical staging systems

• For OS, serum EFEMP1 levels correlate with the Enneking staging system (r = 0.32, P = 0.021)

• Analyze relationship with metastatic status; in OS, EFEMP1 levels strongly correlate with lung metastasis (r = 0.50, P < 0.001)

Tissue-serum correlation analysis:

• Compare EFEMP1 expression in tissue samples (via IHC) with serum levels (via ELISA)

• Strong correlations between tissue expression and serum levels support the biological relevance of circulating EFEMP1

• In OS patients, this correlation is significant (r = 0.49, P < 0.001)

Longitudinal monitoring:

• Track EFEMP1 levels during disease progression and treatment

• Surgical and chemotherapeutic interventions may influence serum EFEMP1 levels

• Changes in levels may provide insights into treatment response or disease recurrence

The table below summarizes key correlations between serum EFEMP1 levels and clinical parameters in osteosarcoma patients:

These methodological approaches enable the systematic investigation of EFEMP1 as a cancer biomarker, providing both diagnostic and prognostic information.

How does EFEMP1 contribute to signaling pathways in cancer progression?

EFEMP1's role in cancer progression involves several key signaling mechanisms that can be studied using appropriate antibody-based techniques:

EGFR signaling pathway analysis:

• EFEMP1 binds to EGFR, inducing receptor autophosphorylation and activating downstream signaling cascades

• To investigate this interaction, researchers can employ:

  • Co-immunoprecipitation using EFEMP1 antibodies to pull down EGFR complexes

  • Proximity ligation assays to visualize EFEMP1-EGFR interactions in situ

  • Phospho-specific antibodies to assess EGFR activation status following EFEMP1 treatment

Cell-matrix interaction studies:

• EFEMP1 exhibits functional relationships with extracellular matrix proteins like fibronectin and integrins

• These interactions influence cell adhesion, migration, and invasion capabilities

• Methodological approaches include:

  • Adhesion assays comparing wild-type and EFEMP1-depleted cells

  • Migration/invasion assays with EFEMP1 antibody neutralization

  • Immunofluorescence co-localization studies using EFEMP1 antibodies alongside ECM protein markers

Chondrocyte differentiation regulation:

• EFEMP1 may function as a negative regulator of chondrocyte differentiation

• This regulatory function can be examined through:

  • Differentiation assays with EFEMP1 knockdown/overexpression

  • Expression analysis of chondrogenic markers in relation to EFEMP1 levels

  • Immunohistochemical studies of growth plate development using EFEMP1 antibodies

Understanding these signaling mechanisms provides insight into how EFEMP1 contributes to cancer progression and identifies potential therapeutic targets. Appropriate antibody selection is crucial for these investigations, with attention to specificity, affinity, and application compatibility.

What are common issues when working with EFEMP1 antibodies and how can they be resolved?

Researchers may encounter several challenges when working with EFEMP1 antibodies. Here are methodological approaches to identify and resolve these issues:

Weak or absent signal:

• Problem diagnosis: Perform positive control experiments using cell lines known to express EFEMP1

• Resolution strategies:

  • Increase antibody concentration (e.g., from 1:1000 to 1:500 for Western blot)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Enhance signal development time or switch to more sensitive detection systems

  • For tissue sections, optimize antigen retrieval methods (try citrate buffer pH 6.0 in microwave)

Non-specific binding:

• Problem diagnosis: Compare staining pattern with published literature and RNA expression data

• Resolution strategies:

  • Increase blocking time and concentration

  • Perform peptide competition assays to confirm specificity

  • Try alternative antibody clones (consider switching from polyclonal to monoclonal)

  • Include additional washing steps with higher detergent concentration

Inconsistent results between experiments:

• Problem diagnosis: Implement standardized positive controls in each experiment

• Resolution strategies:

  • Standardize protein loading for Western blot (verify with housekeeping protein controls)

  • Maintain consistent incubation times and temperatures

  • Prepare fresh working dilutions of antibodies for each experiment

  • Consider lot-to-lot variations when purchasing new antibody supplies

Cross-reactivity with other fibulin family members:

• Problem diagnosis: Test antibody against recombinant fibulin family proteins

• Resolution strategies:

  • Select antibodies targeting unique regions of EFEMP1 not shared with other fibulins

  • Validate specificity through knockout/knockdown experiments

  • Use multiple antibodies targeting different epitopes to confirm findings

By systematically addressing these issues with appropriate methodological modifications, researchers can optimize their EFEMP1 antibody-based experiments for consistent, specific, and sensitive detection.

How can I validate the specificity of my EFEMP1 antibody?

Comprehensive validation of EFEMP1 antibody specificity is crucial for generating reliable research data. The following methodological approaches should be implemented:

Positive and negative control samples:

• Test antibody against cell lines with known EFEMP1 expression levels

• Include genetic controls such as:

  • EFEMP1 knockout/knockdown samples

  • EFEMP1-overexpressing transfected samples (as demonstrated with 293T cells)

• Compare staining patterns with published RNA expression data for correlation

Multiple detection techniques:

• Confirm specificity across different applications (WB, IHC, ICC, etc.)

• For each technique, verify that the observed molecular weight matches the expected 54.6 kDa

• Compare results between different antibody clones targeting distinct EFEMP1 epitopes

Peptide competition assays:

• Pre-incubate antibody with immunizing peptide or recombinant EFEMP1

• This should abolish or significantly reduce specific binding

• Use structurally similar proteins as negative controls in competition assays

Cross-species reactivity assessment:

• If antibody claims multi-species reactivity, test across all relevant species

• Compare sequence homology in the epitope region across species

• Adjust protocols (dilution, incubation time) for optimal performance in each species

Mass spectrometry validation:

• For ultimate confirmation, perform immunoprecipitation followed by mass spectrometry

• This identifies all proteins pulled down by the antibody, confirming EFEMP1 specificity

These systematic validation approaches ensure that experimental findings genuinely reflect EFEMP1 biology rather than artifacts of non-specific antibody binding, providing a solid foundation for subsequent research.

How can EFEMP1 antibodies be utilized in translational research?

EFEMP1 antibodies offer several methodological approaches for translational research that bridges laboratory findings with clinical applications:

Biomarker development pipeline:

• Develop standardized ELISA protocols for serum EFEMP1 quantification

• Establish reference ranges in healthy populations (approximately 1.47 ng/ml)

• Define diagnostic cutoff values based on ROC curve analysis (e.g., 1.51 ng/ml for OS)

• Validate sensitivity and specificity across diverse patient cohorts

• Compare performance against existing clinical biomarkers

Therapeutic target validation:

• Use neutralizing antibodies to block EFEMP1 function in preclinical models

• Assess changes in:

  • EGFR signaling pathway activation

  • Cell migration and invasion capabilities

  • Tumor growth and metastasis in animal models

• These approaches can validate EFEMP1 as a potential therapeutic target

Companion diagnostic development:

• Standardize immunohistochemical protocols for tissue EFEMP1 assessment

• Correlate expression patterns with treatment response

• Develop scoring systems based on staining intensity and distribution

• Evaluate potential as a companion diagnostic for targeted therapies

Disease monitoring methodologies:

• Establish protocols for longitudinal EFEMP1 monitoring during treatment

• Correlate changes with disease progression or regression

• In animal models, serum EFEMP1 levels correlate with tumor progression

• Standardize collection time points and sample handling procedures

These translational approaches leverage EFEMP1 antibodies to develop clinically relevant tools for diagnosis, prognosis, treatment selection, and disease monitoring, potentially improving patient outcomes through personalized medicine approaches.

What are the considerations for multiplexed detection of EFEMP1 with other biomarkers?

Multiplexed detection of EFEMP1 alongside other biomarkers provides comprehensive insight into disease mechanisms. The following methodological approaches optimize multiplexed analysis:

Antibody compatibility assessment:

• Test for cross-reactivity between primary antibodies from different species

• Validate secondary antibody specificity to prevent cross-detection

• Optimize antibody dilutions when used in combination

• Consider using directly conjugated primary antibodies to eliminate secondary antibody complications

Sequential multiplexed immunohistochemistry:

• Perform sequential staining with intermediate stripping steps

• Validate complete removal of previous antibodies before subsequent staining

• Document tissue integrity throughout multiple staining cycles

• Include single-stain controls for comparison

Multicolor immunofluorescence techniques:

• Select fluorophores with minimal spectral overlap

• Include appropriate compensation controls

• Consider antibody combinations based on cellular localization patterns:

  • EFEMP1 (extracellular matrix) with membrane receptors like EGFR

  • EFEMP1 with downstream signaling components

Multiplex ELISA methodologies:

• Develop bead-based multiplex assays for simultaneous detection

• Validate absence of interference between capture antibodies

• Establish standard curves for each analyte individually and in combination

• Assess potential matrix effects when measuring multiple proteins

By implementing these methodological considerations, researchers can develop robust multiplexed detection systems that provide comprehensive biomarker profiles, enhancing both mechanistic understanding and clinical utility of EFEMP1 in conjunction with other relevant markers.